151 related articles for article (PubMed ID: 37658645)
21. COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis.
Demolder S; Schaevers V; Lagrou K; De Munter P; Beeckmans H; Verleden GM; Godinas L; Dupont LJ; Van Bleyenbergh P; Lorent N; Vos R
Transpl Int; 2024; 37():12061. PubMed ID: 38328617
[TBL] [Abstract][Full Text] [Related]
22. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
Ustianowski A
Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.
Soeroto AY; Yanto TA; Kurniawan A; Hariyanto TI
Rev Med Virol; 2023 Mar; 33(2):e2420. PubMed ID: 36617704
[TBL] [Abstract][Full Text] [Related]
24. Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan.
Kawashima I; Hyuga H; Nakadate A; Matsuura M; Sakamoto Y; Suzuki J; Kumagai T; Suzuki M; Koshiishi M; Yamamoto T; Nakajima K; Tanaka M; Kirito K
Int J Hematol; 2023 Dec; 118(6):731-736. PubMed ID: 37747583
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
Levin MJ; Ustianowski A; De Wit S; Beavon R; Thissen J; Seegobin S; Dey K; Near KA; Streicher K; Kiazand A; Esser MT
Infect Dis Ther; 2024 Jun; 13(6):1253-1268. PubMed ID: 38703336
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab.
Sciascia S; Rilat MLA; Fenoglio R; Foddai SG; Radin M; Cecchi I; Cinnirella G; Crosasso P; Guidetti MG; Barinotti A; Baldovino S; Menegatti E; Roccatello D
Clin Kidney J; 2023 Sep; 16(9):1465-1468. PubMed ID: 37664578
[TBL] [Abstract][Full Text] [Related]
27. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G
Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204
[No Abstract] [Full Text] [Related]
28. Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases.
Thomas M; Masson M; Bitoun S; Hamroun S; Seror R; Dupuy H; Lazaro E; Richez C; Allanore Y; Avouac J
Rheumatology (Oxford); 2024 May; 63(6):1632-1638. PubMed ID: 37632774
[TBL] [Abstract][Full Text] [Related]
29. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Svizzeretto E; Tommasi A; Pallotto C; Schiaroli E; Francisci D
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543720
[TBL] [Abstract][Full Text] [Related]
30. Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients With Systemic Autoimmune Rheumatic Diseases.
Kawano Y; Wang X; Patel NJ; Qian G; Kowalski E; Bade KJ; Vanni KMM; Jonsson AH; Williams ZK; Cook CE; Srivatsan S; Wallace ZS; Sparks JA
J Rheumatol; 2024 Mar; 51(3):305-312. PubMed ID: 37839812
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
Demel I; Skopal D; Šafránková E; Rozsívalová P; Jindra P; Šrámek J; Turková A; Vydra J; Labská K; Vedrová J; Čerňan M; Szotkowski T; Móciková H; Hynková L; Šušol O; Kováčová I; Belada D; Hájek R
Ann Hematol; 2024 Mar; 103(3):981-992. PubMed ID: 38092996
[TBL] [Abstract][Full Text] [Related]
32. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients.
Laracy JC; Yan J; Steiger SN; Tan CA; Cohen N; Robilotti EV; Fender J; Cohen S; Korde N; Lee-Teh M; Noy A; Oved JH; Roeker LE; Shah G; Babady NE; Kamboj M; Seo SK
Haematologica; 2023 Nov; 108(11):3058-3067. PubMed ID: 37345467
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
Bender Ignacio RA; Chew KW; Moser C; Currier JS; Eron JJ; Javan AC; Giganti MJ; Aga E; Gibbs M; Tchouakam Kouekam H; Johnsson E; Esser MT; Hoover K; Neytman G; Newell M; Daar ES; Fischer W; Fletcher CV; Li JZ; Greninger AL; Coombs RW; Hughes MD; Smith D; Wohl DA;
JAMA Netw Open; 2023 Apr; 6(4):e2310039. PubMed ID: 37099295
[TBL] [Abstract][Full Text] [Related]
34. Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
Tuffy KM; Ahani B; Aksyuk AA; Avila M; Brady T; Kijak GH; Koh G; Levin MJ; Roe TL; Schuko N; Thissen J; Ustianowski A; Zhang T; Kelly EJ; Streicher K
J Infect Dis; 2023 Oct; 228(8):1055-1059. PubMed ID: 37280116
[TBL] [Abstract][Full Text] [Related]
35. Tixagevimab/cilgavimab for the prevention of COVID-19 in vaccine-refractory patients with autoimmune diseases: a prospective cohort study.
Minopoulou I; Tascilar K; Corte G; Mutlu MY; Schmidt K; Bohr D; Hartmann F; Manger K; Manger B; Korn K; Kleyer A; Simon D; Harrer T; Schett G; Fagni F
Rheumatology (Oxford); 2024 May; 63(5):1377-1383. PubMed ID: 37531288
[TBL] [Abstract][Full Text] [Related]
36. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era.
Ntanasis-Stathopoulos I; Filippatos C; Gavriatopoulou M; Malandrakis P; Eleutherakis-Papaiakovou E; Spiliopoulou V; Syrigou RE; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Kastritis E; Dimopoulos MA; Terpos E
Diseases; 2023 Sep; 11(3):. PubMed ID: 37754319
[No Abstract] [Full Text] [Related]
37. Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak.
You J; Tian J; Wu H; Kang W; Wen J; Xu H; Shi W; Wang Z; Wei H; Du Y; Li X; Mu G; Zhou M; Gu Z; Qu J
Expert Rev Anti Infect Ther; 2023; 21(12):1365-1371. PubMed ID: 37855094
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab.
Duminuco A; Romano A; Leotta D; La Spina E; Cambria D; Bulla A; Del Fabro V; Tibullo D; Giallongo C; Palumbo GA; Conticello C; Di Raimondo F
Front Oncol; 2023; 13():1157610. PubMed ID: 37064138
[TBL] [Abstract][Full Text] [Related]
39. Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation.
Falcone M; Tiseo G; Marchetti G; Kalo J; Galfo V; Occhineri S; Almerigogna F; Matucci T; Riccardi N; Suardi LR; Rina I; Sijoni L; Caparello MC; Cassano Cassano R; Del Giudice ML; Franciosa M; Facella F; Tancredi G; Fazzi R; Galimberti S
Leuk Lymphoma; 2024 Jun; ():1-8. PubMed ID: 38832710
[TBL] [Abstract][Full Text] [Related]
40. Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience.
Akinosoglou K; Rigopoulos EA; Kaiafa G; Daios S; Karlafti E; Ztriva E; Polychronopoulos G; Gogos C; Savopoulos C
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
